Search Result

Results for "

IRAK4+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Cyclic GMP-AMP Synthase (1) Endogenous Metabolite (2) ERK (1) FLT3 (2) IFNAR (1) Interleukin Related (1) IRAK (51) Ligands for Target Protein for PROTAC (1) NF-κB (3) p38 MAPK (1) PROTACs (4) Reference Standards (2) TNF Receptor (2) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (21) Infection (1) Inflammation/Immunology (34) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18992

AS2444697	IRAK	Inflammation/Immunology
AS2444697 is an orally active *IRAK-4* inhibitor with an IC₅₀ of 21 nM . AS2444697 potently inhibits human and rat IRAK-4 activity. AS2444697 exhibits renoprotective effects through anti-inflammatory action .

HY-139374

Zabedosertib 2 Publications Verification BAY 1834845	IRAK	Inflammation/Immunology
Zabedosertib (BAY 1834845) is a selective, orally active *IRAK4* inhibitor with immunomodulatory potential, IC₅₀ is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .

HY-111101

AZ1495	IRAK	Cancer
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 *(IRAK4)* inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC₅₀ values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a K_d value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-101922

IRAK4-IN-1	IRAK	Inflammation/Immunology
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-114181

IRAK4-IN-4 1 Publications Verification	IRAK Cyclic GMP-AMP Synthase	Inflammation/Immunology
IRAK4-IN-4 (Compound 15) is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, with an IC₅₀ of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC₅₀ of 2.1 nM. IRAK4-IN-4 can be used for research of autoimmune diseases .

HY-13275

IRAK inhibitor 1	IRAK	Inflammation/Immunology
IRAK inhibitor 1 is a potent *IRAK-4* inhibitor with IC₅₀ of 216 nM, is poorly active against JNK-1 and JNK-2 with IC₅₀ of 3.801 μM, and >10 μM, respectively.

HY-147264

Edecesertib GS-5718	IRAK	Inflammation/Immunology
Edecesertib (GS-5718) is a selective, potent, orally active *IRAK-4* inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research ^[4] .

HY-109585

IRAK4-IN-7	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .

HY-153224

GLPG2534	IRAK	Inflammation/Immunology
GLPG2534 is an orally active and selective *IRAK4* inhibitor, with IC₅₀ values of 6.4 nM and 3.5 nM for human and mouse IRAK4. GLPG2534 can be used for the research of inflammatory skin diseases .

HY-150735

IRAK4-IN-20	IRAK	Inflammation/Immunology
IRAK4-IN-20 (Compound BAY-1834845) is an orally active *IRAK4* inhibitor with an IC₅₀ of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .

HY-151363

IRAK4-IN-21	IRAK	Inflammation/Immunology
IRAK4-IN-21 (compound 17) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 5 and 56 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-151365

IRAK4-IN-22	IRAK	Inflammation/Immunology
IRAK4-IN-22 (compound 18) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 3 and 17 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-146112

IRAK4-IN-14	IRAK	Cancer
IRAK4-IN-14 (compound 28) is a potent, selective and orally active *IRAK4* inhibitor with an IC₅₀ of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib .

HY-162359

BIO-7488	IRAK	Neurological Disease Inflammation/Immunology
BIO-7488 is an orally active, selective and blood-brain barrier permeable *IRAK4* inhibitor, with an IC₅₀ value of 0.5 nM. BIO-7488 inhibits the production of pro-inflammatory cytokines (IL-1β, TNFα, IL-6) and demonstrates anti-inflammatory effects in both LPS (HY-D1056) and distal hypoxic-middle cerebral artery occlusion (DH-MCAO) ischemic stroke model. BIO-7488 can be used for the study of neuroinflammatory-related diseases, particularly ischemic stroke .

HY-131903

HS271	IRAK	Inflammation/Immunology
HS271 is a highly potent, orally active and selective *IRAK4* inhibitor, with an IC₅₀ of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties .

HY-130253

IRAK4-IN-6	IRAK	Cancer
IRAK4-IN-6 is an orally efficacious and selective *IRAK4* inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma .

HY-148276

KTX-497	PROTACs IRAK	Cancer
KTX-497 is an *IRAK4* PROTAC degrader with a DC₅₀ value of 3 nM. KTX-497 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-13278

IRAK inhibitor 4 1 Publications Verification	IRAK	Inflammation/Immunology
IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

HY-178012

GLPG4471	IRAK TNF Receptor	Inflammation/Immunology
GLPG4471 is a selective and orally active *IRAK4* inhibitor with an IC₅₀ of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .

HY-124995

BMS-986126	IRAK Toll-like Receptor (TLR) ERK NF-κB Interleukin Related	Inflammation/Immunology
BMS-986126 is a potent, selective, and orally active *IRAK4* inhibitor (IC₅₀ = 5.3 nM). BMS-986126 broadly inhibits MyD88-dependent signaling pathways. BMS-986126 demonstrates robust activity in the MRL/lpr and NZB/NZW murine models of lupus, inhibiting multiple pathogenic responses. BMS-986126 can be used for autoimmune diseases research, such as lupus erythematosus (SLE) .

HY-179095

UR241-2	Ligands for Target Protein for PROTAC IRAK NF-κB p38 MAPK	Cancer
UR241-2 is an *IRAK4* inhibitor. UR241-2 suppresses IL-1–induced *IRAK1/4* signaling, NF-κβ activation, and phosphorylation of p65 and p38. UR241-2 selectively inhibits leukemia stem cell clonogenicity. UR241-2 can serve as a ligand for target proteins for PROTAC, facilitating the development and design of PROTAC degraders for IRAK4. UR241-2 can be used in the research of acute myeloid leukemia .

HY-W900240

BMS-978299	IRAK	Inflammation/Immunology
BMS-978299 is an *IRAK4* inhibitor that can be used for the study of immune disorders .

HY-143231

IRAK4-IN-8	IRAK	Infection
IRAK4-IN-8 (VI-177) is a potent *IRAK4* inhibitor .

HY-168982

Lomonitinib	FLT3 IRAK	Cancer
Lomonitinib is a highly potent and selective pan-FLT3/IRAK4* inhibitor* with antitumor activity. Lomonitinib is promising for research of myeloid leukemia .

HY-13278A

IRAK inhibitor 4 (trans)	IRAK	Inflammation/Immunology
IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor.

HY-150594

IRAK4-IN-17	IRAK NF-κB	Cancer
IRAK4-IN-17 (Compound 5) is a potent *IRAK4* inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

HY-155519

IRAK4-IN-26	IRAK	Inflammation/Immunology
IRAK4-IN-26 (Compound 21) is a *IRAK4* inhibitor (IC₅₀: 6.2 nM). IRAK4-IN-26 displays an oral bioavailability of 21%. IRAK4-IN-26 can be used for research of inflammatory and autoimmune disorders .

HY-143485

IRAK4-IN-9	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-9 (compound 73) is a potent *IRAK4* inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-9 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-148277

KTX-612	PROTACs IRAK	Cancer
KTX-612 is an orally active *IRAK4* PROTAC degrader with a DC₅₀ value of 7 nM. KTX-612 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-120041

ND-2158	IRAK	Cancer
ND-2158 is a competitive *IRAK4* inhibitor, with the K_i of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo .

HY-174843

IRAK4-IN-32	IRAK	Inflammation/Immunology
IRAK4-IN-32 (Compound 10) is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an enzymatic IC₅₀ value of 18.86 nM and a cellular IC₅₀ value of 6.19 nM. IRAK4-IN-32 is promising for research of inflammatory and autoimmune diseases .

HY-169057

BI1543673	IRAK Toll-like Receptor (TLR)	Inflammation/Immunology
BI1543673 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. BI1543673 can reduce the inflammatory response stimulated by *TLR4* and TLR7/8 in human lung tissue. BI1543673 can decrease inflammatory signaling in a mouse model of lung inflammation induced by LPS .

HY-155132

IRAK4-IN-28	IRAK	Inflammation/Immunology
IRAK4-IN-28 (compound 42) is an orally active *IRAK4* inhibitor (IC₅₀=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases .

HY-150733

IRAK4-IN-19	IRAK	Inflammation/Immunology
IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease .

HY-117622

ND-2110	IRAK	Inflammation/Immunology Cancer
ND-2110 is a selective *IRAK4* inhibitor (K_i: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .

HY-176735

*FLT3/IRAK4-IN-1*	IRAK FLT3 Apoptosis	Cancer
FLT3/IRAK4-IN-1 is a selective *FLT3/IRAK4* inhibitor with the remarkable activity towards FLT3-WT (IC₅₀ = 1.95 nM), FLT3-D835Y (IC₅₀ = 3.22 nM) and *IRAK4* (IC₅₀ = 53.72 nM). LT3/IRAK4-IN-1 has relatively low toxicity to normal bone marrow cells, can effectively promote cell apoptosis, and has the potential to overcome drug resistance. FLT3/IRAK4-IN-1 can be used for research on acute myeloid leukemia (AML) .

HY-176197

IRAK4-IN-31	IRAK	Cancer
IRAK4-IN-31 (Compound II) is a crystalline *IRAK4* inhibitor. IRAK4-IN-31 can be used in myelodysplastic syndrome (MDS) research .

HY-149345

IRAK4-IN-24	IRAK	Inflammation/Immunology
IRAK4-IN-24 (compound 16) is a potent *IRAK4* inhibitor, with high clearance (Cl) and poor oral bioavailability. IRAK4-IN-24 can be used for research in inflammatory and autoimmune disorders.

HY-146073

IRAK4-IN-12	IRAK	Cancer
IRAK4-IN-12 (compound 37) is a potent *IRAK4* inhibitor with an IC₅₀ of 0.015 µM. IRAK4-IN-12 shows cell pIRAK4 potencies with an IC₅₀ of 0.5 µM .

HY-146072

IRAK4-IN-11	IRAK	Cancer
IRAK4-IN-11 (compound 6) is a potent *IRAK4* inhibitor with an IC₅₀ of 0.008 µM. IRAK4-IN-11 shows cell pIRAK4 potencies with an IC₅₀ of 0.19 µM .

HY-146111

IRAK4-IN-13	IRAK	Cancer
IRAK4-IN-13 (compound 21) is a potent and selective *IRAK4* inhibitor with an IC₅₀ of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg .

HY-143486

IRAK4-IN-10	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-10 (compound 75) is a potent *IRAK4* inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-10 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-158760

*PROTAC IRAK4* degrader-11**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-11 (compound 15) is PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 96.25% and the DC₅₀ of 2.29 nM in HEK293 cells(Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker；Pink: IRAK4 inhibitor) .

HY-18992R

AS2444697 (Standard)	Reference Standards IRAK	Inflammation/Immunology
AS2444697 (Standard) is the analytical standard of AS2444697 (HY-18992). This product is intended for research and analytical applications. AS2444697 is an orally active *IRAK-4* inhibitor with an IC₅₀ of 21 nM. AS2444697 potently inhibits human and rat IRAK-4 activity. AS2444697 exhibits renoprotective effects through anti-inflammatory action.

HY-168586

*PROTAC IRAK4* degrader-12**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-12 is a PROTAC based on Cereblon ligand, inducing a maximum degradation rate of IRAK4 of 108.46% in K562 cells with an IC₅₀ value of 4.87 nM ( Structure Note: Pink, IRAK4 inhibitor (HY-168611); Blue, E3 (HY-W733885); Black, linker (HY-168613)) .

HY-150732

IRAK4-IN-18	IRAK	Inflammation/Immunology
IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease .

HY-155518

IRAK4-IN-25	IRAK	Inflammation/Immunology
IRAK4-IN-25 (compound 38) is an orally acitve and potent IRAK4 inhibitor (IC₅₀=7.3 nM), with low clearance (Cl=12 mL/min/kg). IRAK4-IN-25 inhibits production of pro-inflammatory cytokines, and shows in vitro safety and ADME profiles. IRAK4-IN-25 can be used for research in inflammatory and autoimmune disorders .

HY-146113

IRAK4-IN-15	IRAK	Cancer
IRAK4-IN-15 (compound 35) is a potent and selective *IRAK4* inhibitor with an IC₅₀ of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .

HY-101922R

IRAK4-IN-1 (Standard)	Reference Standards IRAK	Inflammation/Immunology
IRAK4-IN-1 (Standard) is the analytical standard of IRAK4-IN-1 (HY-101922). This product is intended for research and analytical applications. IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-116184

PF-05387252	Endogenous Metabolite	Inflammation/Immunology
PF-05387252 is a potent and selective IRAK4 inhibitor with the activity of inhibiting endogenous TLR signaling pathways. PF-05387252 has shown anti-inflammatory activity in experimental models and may have potential clinical application value in inhibiting psoriasis. Although PF-05387252 and its related compounds have shown anti-inflammatory effects in animal models, their efficacy in inhibiting psoriasis has not yet been verified .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

IRAK4+inhibitor

Inhibitors & Agonists